PowerShares DWA Healthcare Momentum Portfolio PTH 深 沪
等待开盘 09-20 09:30:00 美东时间
40.53
-0.298
-0.73%
华盛通- 最 高40.98
- 今 开40.98
- 成交量 4399股
- 最 低 40.515
- 昨 收 40.8279
- 总市值 1.08亿
- 52周最高 48.63
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 33.5611
- 委 比 57.14%
- 总股本 266.00万
- 历史最高 64.6295
- 量 比 0.83
- 振 幅 1.14%
- 历史最低 6.9445
- 每 手 1
- 风险率 3.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
09-18 23:51
重磅收购取得新进展！9100亿芯片巨头明起复牌 | 盘后公告精选
国产“芯片一哥”明起复牌，PCB概念股异动期间实控人减持30万股公司股份，这一机器人概念股控制权恐生变......
09-08 21:17
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, and CFO, Frank Knuettel, will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 1:30 p.m. ET. The presentation will be available via webcast on Pelthos' website, with an archive available for 90 days. Pelthos, a biopharmaceutical company, focuses on innovative therapeutic products, with its lead product, ZELSUVMI™, approved for molluscum contagiosum treatment.
09-02 12:00
Ascendis Pharma To Present New Data From Week 156 Of Phase 3 PaTHway Trial Demonstrating Safety And Efficacy Of Long-Term Treatment With TransCon PTH In Adults With Hypoparathyroidism, At ENDO 2025
Ascendis Pharma A/S (NASDAQ:ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from
07-08 04:03
Why Is Channel Therapeutics Stock Surging On Friday?
Channel Therapeutics shares rise after announcing 10-for-1 reverse stock split and upcoming rebrand.
06-27 23:55
The Analyst Verdict: Septerna In The Eyes Of 4 Experts
4 analysts have shared their evaluations of Septerna (NASDAQ:SEPN) during the r...
06-23 20:02
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential.
2024-08-23 02:26
